Grade My Investments
HomeFree Stock Grades › MNKD

MannKind Corporation (MNKD) Stock Grade

MNKD · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.7B
P/E Ratio
295.6
Revenue Growth (YoY)
+22.2%
Net Margin
1.7%
Return on Equity
Dividend Yield
None

About MannKind Corporation's fundamentals

MannKind Corporation, a biotechnology company with a $1.7B market cap, is experiencing solid revenue growth of 22.2% year-over-year, indicating expanding commercial traction. However, the company operates with a thin net margin of 1.7%, meaning it retains only a small portion of each revenue dollar as profit. The stock trades at a notably elevated P/E ratio of 295.6, reflecting significant investor expectations for future earnings growth, while the company currently pays no dividend and shows no positive return on equity, suggesting it is not yet generating sustainable profits on shareholder capital.

Track MNKD free — no credit card required. Live grade + monthly AI report →